Du är här

2015-08-25

MorphoSys AG: MorphoSys and Immatics Biotechnologies Enter Strategic Alliance in Immuno-oncology

MorphoSys AG / MorphoSys and Immatics Biotechnologies Enter Strategic Alliance
inImmuno-oncology . Processed and transmitted by NASDAQ OMX Corporate
Solutions.The issuer is solely responsible for the content of this
announcement.
Collaboration Aims to Develop Novel Antibody-Based Therapies
Targeting Tumor-Associated Peptides Derived From Intracellular Proteins

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and
Immatics Biotechnologies GmbH announced today a strategic alliance to
generate novel antibody-based therapeutics against multiple proprietary
cancer antigens recognized by T cells. The collaboration agreement provides
MorphoSys with access to several proprietary tumor-associated peptides
(TUMAPs) discovered using Immatics' XPRESIDENT® platform to develop novel
antibody-based therapeutics against these targets in a number of solid and
hematological cancers. XPRESIDENT® enables access to novel antibody targets
associated with proteins that are present inside cancer cells. In return,
Immatics will be provided with MorphoSys' Ylanthia® antibodies against a
number of its TUMAPs, with proprietary development rights. The companies will
pay each other milestones based on their respective development progress as
well as royalties on marketed products. Financial details of the agreement
were not disclosed.

Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG, commented: "We
are delighted to join forces with Immatics, a world leader in discovering
truly novel cancer targets that would be otherwise inaccessible for
antibody-based therapies. This alliance opens up the intracellular target
space for us and thus complements the therapeutic approaches we use in other
oncology programs. We believe this collaboration will create several unique
product opportunities for us based on truly differentiated compounds."

Dr. Harpreet Singh, Chief Scientific Officer of Immatics Biotechnologies GmbH,
added: "The alliance with MorphoSys marks an important strategic milestone
for Immatics. We are now entering the field of antibody-based therapeutics
complementing our existing cancer immunotherapy pipeline. The combination of
MorphoSys' outstanding capabilities to create antibodies and the unique
access to intracellular targets through our XPRESIDENT® discovery engine
provides both partners the opportunity to jointly deliver the next generation
of transforming antibody drugs for cancer patients with high unmet medical
need."

Tumor cells differ from healthy cells in the expression of tumor-associated
proteins. These proteins are degraded inside living cells into shorter
fragments, called peptides, which are then shuttled to the cell surface.
Specialized receptors on the cell surfaces, so-called major
histocompatibility complex (MHC) receptors, display these peptides to the
external environment thereby providing a snapshot of the cell's interior. The
therapeutic programs now being pursued by Immatics and MorphoSys aim to
discover Ylanthia® antibodies against these MHC-bound peptide targets in
order to kill the tumor cells. Immatics' XPRESIDENT® discovery platform is
the only known high-throughput research technology to directly identify,
quantify, and prioritize these cancer-related peptides.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 100 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys,
visithttp://www.morphosys.com.

About Immatics:
Immatics Biotechnologies GmbH is a clinical-stage biopharmaceutical company
and a global leader in cancer immunotherapy with the leading target discovery
platform. Its target discovery engine XPRESIDENT® enables Immatics to
discover novel relevant tumor-associated peptide (TUMAP) antigens derived
from cellular (both intracellular and surface) proteins. These TUMAPs are
presented by Human Leukocyte Antigen (HLA) receptors on the surface of tumor
cells and constitute the basis for developing a range of rationally designed
cancer immunotherapies such as cancer vaccines, protein-based compounds
including antibodies and soluble T-cell receptors and adoptive cellular
therapies. The targets discovered by Immatics have a major advantage compared
to other indirect approaches in that they are confirmed to be naturally
expressed in primary cancer tissue.
Immatics' lead product, IMA901, is in a pivotal phase 3 study. Immatics'
cancer vaccine pipeline also includes IMA910 for treatment of advanced
colorectal cancer, and IMA950 for the treatment of glioma. Immatics signed a
cancer immunotherapy collaboration with Roche in 2013 to research, develop
and commercialize a number of new cancer peptide antigen based
immunotherapies, targeting primarily gastric, prostate and non-small cell
lung cancer. Immatics is based in Tuebingen, Munich and Houston, TX, and
employs over 90 employees (FTEs) dedicated to the fight against cancer.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group. XPRESIDENT® is a registered
trademark of Immatics Biotechnologies GmbH.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties. Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned.

For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications&IR

Mario Brkulj
Associate Director Corporate Communications&IR

Alexandra Goller
Manager Corporate Communications&IR

Phone: +49 89 89927-404
investors@morphosys.com

Immatics Biotechnologies GmbH
Dr. Nikola Wiegeler
Phone: +49 7071 5397-110

Claudia Biesinger
Phone: +49 7071 5397-131

media@immatics.com

Citigate Dewe Rogerson
David Dible
Phone: +44 207 638-9571
david.dible@citigatedr.co.uk

Media Release (PDF)
http://hugin.info/130295/R/1947015/706827.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire

HUG#1947015

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.